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Selective inhibition of the kinase DYRK1A
by targeting its folding process
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Tomoe Kato-Sumida3,w, Yuka Koike1,2, Minako Abe5, Yosuke Nonaka5, Teikichi Ikura5, Nobutoshi Ito5,
Hiroshi Shibuya4, Takamitsu Hosoya3 & Masatoshi Hagiwara1
Autophosphorylation of amino-acid residues is part of the folding process of various protein
kinases. Conventional chemical screening of mature kinases has missed inhibitors that
selectively interfere with the folding process. Here we report a cell-based assay that evaluates
inhibition of a kinase at a transitional state during the folding process and identify a folding
intermediate-selective inhibitor of dual-speciﬁcity tyrosine-phosphorylation-regulated
kinase 1A (DYRK1A), which we refer to as FINDY. FINDY suppresses intramolecular
autophosphorylation of Ser97 in DYRK1A in cultured cells, leading to its degradation, but does
not inhibit substrate phosphorylation catalysed by the mature kinase. FINDY also suppresses
Ser97 autophosphorylation of recombinant DYRK1A, suggesting direct inhibition, and shows
high selectivity for DYRK1A over other DYRK family members. In addition, FINDY rescues
DYRK1A-induced developmental malformations in Xenopus laevis embryos. Our study
demonstrates that transitional folding intermediates of protein kinases can be targeted by
small molecules, and paves the way for developing novel types of kinase inhibitors.
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D
ysregulation of protein kinase activity has been implicated
in pathological conditions, such as neurological disorders
and tumorigenesis. The protein kinase family represents
an attractive target for drug development1,2. Kinase inhibitors
that target ATP-binding pockets sometimes cause adverse side
effects by suppressing unintended kinases, because the sequence
and structure of the pockets are well-conserved3. Innovative ideas
are therefore necessary in drug discovery to obtain a highly
selective inhibitor of the target kinase.
DYRK1A, dual-speciﬁcity tyrosine-phosphorylation-regulated
kinase 1A, is a mammalian orthologue of Drosophila minibrain
and is essential for brain development4. The physiological
importance of DYRK1A has been suggested by its proposed
relationship with various symptoms of Down syndrome (DS)5–7.
DYRK1A resides within the obligate trisomic region of human
chromosome 21 and the extra copy of the DYRK1A gene in
people with DS causes a 1.5-fold increased expression of the dual-
speciﬁcity tyrosine-phosphorylation-regulated kinase 1A
(DYRK1A) protein8. The excessive DYRK1A activity is not
only pivotal in causing the characteristic facial features9,10 and
congenital heart defects9 of DS, but is also associated with early-
onset of Alzheimer’s disease11,12. The hypothesis that the elevated
activity of DYRK1A contributes to these neurological disorders
has stimulated an interest in DYRK1A as a potential target for
therapeutic drugs4,12,13. In addition, inhibition of DYRK1A
increases pancreatic b-cell proliferation, suggesting therapeutic
promise for diabetes therapy14,15. To repress the excessive activity
of DYRK1A, we had previously developed a synthetic small
molecule, INDY, which potently suppresses the kinase activity of
DYRK1A. INDY also inhibits other DYRK family members as
well as Cdc2-like kinases16.
DYRKs and glycogen synthase kinase 3b (GSK3b) autopho-
sphorylate their own tyrosine residue in their transitional state
and phosphorylate serine or threonine residues on their
substrates after maturation17–21. Lochhead et al. postulated the
existence of a transitional intermediate of these kinases that has
biochemical properties distinct from the mature state18,19.
Interestingly, the intermediate showed different sensitivity to
chemical inhibitors from the mature kinase. For example, the
transitional intermediate of Drosophila DYRK2 was inhibited by
Purvalanol A, but not by 4,5,6,7-tetrabromo-1H-benzotriazole
(TBB), whereas the mature kinase was inhibited by both18. So far,
selective inhibitors of the transitional intermediate have not yet
been identiﬁed, because the focus of conventional drug screening
has been on the mature forms of the kinases18,22.
Isolation of transitional intermediates is considered to be quite
difﬁcult because of their low population and short lifetimes23.
Therefore, we developed a cell-based assay, named SPHINKS
(substrate phosphorylation by sequential induction of kinase and
substrate), to evaluate intermediate-selective inhibitors of
DYRK1A. Through examination of our synthetic chemical
library, we identiﬁed a small compound, referred to as FINDY
(folding intermediate-selective inhibitor of DYRK1A), which
interfered with the folding process of DYRK1A, but did not
inhibit the substrate phosphorylation catalysed by the mature
kinase. FINDY speciﬁcally suppressed autophosphorylation of
Ser97 in DYRK1A, resulting in its degradation by proteasomes.
Furthermore, we found that FINDY did not affect the kinase
activity of the other members of the DYRK family, indicating the
possibility that transitional intermediate-selective kinase
inhibitors distinguish between the conserved family members.
Results
Design of the cell-based assay targeting the intermediate. To
evaluate intermediate-selective inhibitors of DYRK1A, we
developed the SPHINKS assay, enabling us to evaluate kinase
inhibition at the transitional state during the folding process
(Fig. 1a). We ﬁrst established a HEK293 cell line with dual-
inducible expression of DYRK1A and TAU, a well-characterized
substrate of DYRK1A24,25. Expression of FLAG-tagged DYRK1A
(FLAG-DYRK1A) was controlled by the tet operator, and was
initiated by treatment with doxycycline (Fig. 1b, lanes 4–6). TAU
was expressed in a fused form with the destabilization domain
FKBP12 (DD), which causes degradation of DD fusion proteins
in the absence of a small molecule, Shield-1 (ref. 26). Treatment
with Shield-1 for 2 h stabilized DD-TAU in a dose-dependent
manner (Fig. 1b, lanes 2, 3, 5 and 6). Phosphorylation of the
stabilized DD-TAU at Thr212 was enhanced 4 h after the
administration of doxycycline (Fig. 1b, lanes 5 and 6; and
Supplementary Fig. 1), indicating that DYRK1A is produced from
the doxycycline-induced transcript within 4 h.
To distinguish kinase inhibition at the transitional state from
that after maturation, we set up two types of time courses. Small
molecules were administered either before the induction by
doxycycline (time course: Tc 1) or after the accumulation of
mature DYRK1A (Tc 2; Fig. 1a). Following additional incubation
with Shield-1 for 2 h, total cell lysates were harvested, then
subjected to western blot. If the compound selectively inhibits the
transitional intermediate, but not the mature DYRK1A, it should
suppress TAU phosphorylation in Tc 1, but not in Tc 2, as
illustrated in Fig. 1a.
Identiﬁcation of FINDY. Using the SPHINKS assay, we exam-
ined our chemical library and found a small molecule that sup-
pressed TAU phosphorylation in Tc 1, but not in Tc 2 (Fig. 1c).
This small molecule was referred to as FINDY (Fig. 1d). In
contrast, the canonical DYRK1A inhibitor INDY suppressed
TAU phosphorylation in both Tc 1 and 2 (Fig. 1c).
FINDY is structurally similar to an ATP-competitive inhibitor,
RD0392 (Fig. 1e and Supplementary Fig. 2), which we identiﬁed
through in vitro screening using recombinant DYRK1A. RD0392
bears a ﬁve-membered heterocyclic ring, rhodanine. This moiety
has been reported as a substructure of Pan Assay Interference
Compounds27, which are compounds that have frequently arisen
as hits in high-throughput screening. Conversely, Mendgen et al.
noted that small molecules bearing rhodanine are potentially
valuable and should not be regarded as problematic or
promiscuous binders per se28. Therefore, we synthesized
structural derivatives of RD0392, one of which was FINDY.
In contrast to the dose-dependent inhibition by RD0392 and
INDY in the in vitro assay, FINDY did not exert any observable
inhibitory effect on the recombinant DYRK1A (Fig. 1f). This was
supported by a computational docking simulation study, which
showed that RD0392 was able to ﬁt to the ATP-binding pocket of
mature DYRK1A (Supplementary Fig. 3a,b), whereas FINDY
could not (Supplementary Fig. 3c,d). FINDY decreased the
amount of FLAG-DYRK1A in Tc 1, whereas DD-TAU and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
unaffected. In contrast, the amount of FLAG-DYRK1A was
unaltered in Tc 2 (Fig. 1c). These results suggest that FINDY
selectively impairs the stability or translation of DYRK1A, leading
to the suppression of TAU phosphorylation in Tc 1.
To determine whether the stability or the translation is affected
by FINDY, we constructed a translation reporter system using
ribosome skipping mediated by a 2A peptide. The 2A peptide
inhibits normal peptide bond formation without affecting transla-
tion29, which enables the bicistronic expression of FLAG-DYRK1A
and haemagglutinin (HA)-tagged enhanced green ﬂuorescent
protein (EGFP) (HA-EGFP) under the control of a doxycycline-
driven promoter (Fig. 2a). When administered with doxycycline,
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FINDY decreased the amount of FLAG-DYRK1A in a dose-
dependent manner (EC50 value: 2.2mM), without affecting HA-
EGFP (Fig. 2b). FINDY also decreased the amount of endogenous
DYRK1A in a primary culture of cortical neurons (Fig. 2c). On the
other hand, administration of RD0392 did not decrease the amount
of FLAG-DYRK1A (Fig. 2d). Next, we examined the effect of
FINDY on the degradation of FLAG-DYRK1A in the presence of a
translation inhibitor, cycloheximide. Cells were pre-treated with
doxycycline for 16h, then incubated with cycloheximide and
FINDY. Under this condition, FINDY did not induce the
degradation of FLAG-DYRK1A compared with the vehicle
treatment (Fig. 2e), indicating that FINDY destabilizes newly
translated FLAG-DYRK1A.
FINDY suppresses autophosphorylation on Ser97 of DYRK1A.
Catalytic activity of several protein kinases is regulated by
autophosphorylation to stabilize the active conformation30. To
investigate whether autophosphorylation is involved in the
stabilization of DYRK1A, we prepared a substituted mutant
with Arg (K188R) in place of Lys188. Lys188 in DYRK1A
interacts directly with ATP; the substitution thus renders the
kinase inactive, leading to a ‘kinase-dead’ mutant, which lacks
autophosphorylation ability31. In our study, the K188R mutant
protein of FLAG-DYRK1A was barely detected with western blot,
whereas EGFP from the bicistronic cassette was detected (Fig. 3a,
K188R). This suggests that the abrogation of autophosphorylation
destabilizes the DYRK1A protein. To identify the residues
required for the stabilization of DYRK1A, we mutated
potential autophosphorylation sites. Ser97 and Tyr111 in the
non-catalytic amino-terminal domain of DYRK1A can be
autophosphorylated31. In addition, Tyr319 or Tyr321 in the
activation loop are required to retain catalytic activity31–33, and
the autophosphorylation of these residues has also been
reported21. Similarly, the autophosphorylation of Ser520, which
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Figure 1 | Cell-based assay to evaluate a transitional intermediate-selective inhibitor of DYRK1A. (a) Schematic diagram of the SPHINKS assay.
Doxycycline induces DYRK1A expression. Subsequently, Shield-1 stabilizes TAU fused with the destabilization domain of FKBP12 (DD-TAU). DYRK1A
phosphorylates DD-TAU over the deﬁned time period (19–21 h). Small molecules from our chemical library were added at the indicated points in Tc 1 and 2.
Canonical kinase inhibitors suppress TAU phosphorylation in both Tc 1 and 2. Intermediate-selective inhibitors of DYRK1A should suppress TAU
phosphorylation in Tc 1, but not in Tc 2. (b) Inducible expression of FLAG-DYRK1A and DD-TAU in HEK293 cells. Doxycycline induced FLAG-DYRK1A
expression (lanes 4–6) and Shield-1 stabilized DD-TAU (lanes 2, 3, 5, 6). FLAG-DYRK1A predominantly phosphorylated Thr212 of TAU (p-TAU; lanes 5
and 6). p-TAU, TAU, FLAG and GAPDH were detected by western blot, using their corresponding antibodies. Representative data from the triplicate
experiments are shown. (c) Identiﬁcation of FINDY as the intermediate-selective inhibitor of DYRK1A. TAU phosphorylation was suppressed by FINDY
(10mM) in Tc 1, but not in Tc 2. In contrast, the canonical DYRK1A inhibitor INDY (10mM) suppressed TAU phosphorylation in both Tc 1 and 2.
Representative data from the triplicate experiments are shown. (d) Structure of FINDY. (e) Structure of RD0392, a canonical ATP-competitive inhibitor of
DYRK1A. (f) FINDY did not inhibit the in vitro kinase activity of DYRK1A. Recombinant DYRK1A was incubated with the peptide substrate DYRKtide in the
presence of FINDY, RD0392 or INDY. RD0392 and INDY inhibited the kinase activity with IC50 values of 60.2 and 139 nM, respectively. Representative
dose-response curves with Hill slopes are shown. The results are presented as means±s.d. (n¼4).
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study, is required for its binding to 14-3-3b (ref. 34). Therefore,
we prepared mutants with these residues substituted. The
substituted mutant of S97A and the double mutant of Y321F/
Y319F were degraded, whereas the other mutants remained
(Fig. 3a), indicating that Ser97 and one of the tyrosine residues in
the activation loop are required for the DYRK1A stabilization.
Ser97 and its surrounding amino-acid sequence in DYRK1A
are highly conserved among various species (Fig. 3b), suggesting
their functional importance. To detect phosphorylated Ser97 (p-
Ser97), we generated a polyclonal antibody against p-Ser97, and
transiently transfected 293T cells with the expression vectors of
FLAG-DYRK1A and its mutants, in which the mutants were
detectable, probably because the overexpressed proteins were
beyond the capacity of proteasomal degradation. This antibody
detected the intact DYRK1A (wild type, WT), but barely
identiﬁed the kinase-dead (K188R) and S97A mutants in the
western blot analysis (Fig. 3c). In addition, competition experi-
ments using phospho- and non-phospho-peptides clearly con-
ﬁrmed the antibody’s speciﬁc recognition ability towards p-Ser97
(Supplementary Fig. 4). We then examined whether FINDY
suppresses autophosphorylation. In the presence of FINDY, the
amount of p-Ser97 signiﬁcantly decreased, whereas signals for
phosphorylated tyrosine residues (p-Tyr) were unaffected
(Fig. 3d). In addition, mass spectrometry analysis of the
trypsin-digested peptides of FLAG-DYRK1A showed that FINDY
did not suppress the phosphorylation of Tyr321 in the activation
loop (Supplementary Fig. 5). To conﬁrm that the FINDY-
mediated inhibition of Ser97 autophosphorylation is involved in
degradation of DYRK1A, we examined whether FINDY destabi-
lized the DYRK1A mutants of K188R and S97A, which were not
able to catalyse Ser97 autophosphorylation. FINDY did not
decrease the level of these mutants (Supplementary Fig. 6). Thus,
FINDY acts as an inhibitor of the autophosphorylation and does
not induce DYRK1A degradation by an independent mechanism.
These results thus suggest that FINDY destabilizes DYRK1A by
inhibiting Ser97 autophosphorylation.
To further determine whether Ser97 is autophosphorylated by
an inter- or intramolecular mechanism, we generated HEK293
cells that co-expressed the kinase-dead K188R mutant (FLAG-
DYRK1A K188R) and an intact DYRK1A fused with a DD tag
(DD-FLAG-DYRK1A). If Ser97 autophosphorylation were
mediated by an intermolecular mechanism, Ser97 of the kinase-
dead K188R mutant would be phosphorylated when expressed in
the presence of DD-FLAG-DYRK1A. However, we found that the
overexpressed DD-FLAG-DYRK1A did not enhance the phos-
phorylation of Ser97 in the K188R mutant (Supplementary
Fig. 7a). In addition, DD-FLAG-DYRK1A did not stabilize the
co-expressed K188R protein (Supplementary Fig. 7b). These
results suggest that the Ser97 autophosphorylation of DYRK1A is
catalysed in an intramolecular manner. Furthermore, treatment
with cantharidic acid, a protein phosphatase inhibitor, increased
the amount of p-Ser97 signal in FLAG-DYRK1A (Supplementary
Fig. 7c), suggesting that p-Ser97 is dephosphorylated by a
phosphatase inhibited by cantharidic acid. Interestingly, the
FLAG-DYRK1A protein, which was puriﬁed from HEK293 cells,
did not signiﬁcantly catalyse Ser97 autophosphorylation
(Supplementary Fig. 7d,e). Consistently, FINDY did not decrease
the levels of p-Ser97 in HEK293 cells when cells were treated with
FINDY after the accumulation of mature DYRK1A (Fig. 3e).
Taken together, these results suggest that Ser97 autophosphor-
ylation is catalysed before maturation and that p-Ser97 is
susceptible to dephosphorylation after maturation.
FINDY inhibits incorporation of biotin-ATP. We examined
whether FINDY inhibited incorporation of ATP into the pocket
of DYRK1A. An ATP analogue, the biotinylated acyl phosphate
of ATP, which ﬁts to the ATP-binding pocket of kinases, irre-
versibly reacts with the ATP-orienting lysine and transfers biotin
to this lysine35. We applied this method in designing an
experiment, which is illustrated in Fig. 4a. If FINDY occupies
the ATP-binding pocket of the puriﬁed kinase, it would inhibit
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Figure 2 | FINDYdestabilizes DYRK1A during the folding process. (a) Schematic diagram of the 2A peptide-mediated bicistronic expression of FLAG-DYRK1A
and HA-EGFP. Expression is controlled by the tet operator. Effects of FINDY (b) or RD0392 (d) on destabilization of DYRK1A. FINDY (b) or RD0392 (e) was added
with doxycycline to HEK293 cells harbouring the bicistronic expression vector, which was stably integrated in the genome. After incubation for 5h, total cell lysates
were subjected to SDS–PAGE followed by western blot analysis using the corresponding antibodies against FLAG, HA and GAPDH. Representative data from the
pentaplicate experiments are shown. (c) The amount of endogenous DYRK1A was decreased by FINDY. Primary cortical neurons were cultured in the presence of
FINDY for 3 days. DYRK1A, Tuj1 (neuron-speciﬁc class III b-tubulin) and GAPDH were detected by western blot analysis using their corresponding antibodies.
Representative data from the triplicate experiments are shown. (e) FINDY did not induce the degradation of mature DYRK1A. The cells were treated with
doxycycline for 16h, then incubated with cycloheximide (CHX) with or without FINDY for the indicated time. Total cell lysates were subjected to SDS–PAGE
followed by western blot analysis. Representative data from the triplicate experiments are shown. Conc., concentration.
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the binding of the biotin-ATP analogue to this region. FLAG-
DYRK1A produced in the presence or absence of the small
molecules was immunopuriﬁed from the cells. The biotinylation
of the immunopuriﬁed FLAG-DYRK1A produced in the presence
of FINDY was signiﬁcantly suppressed compared with the vehicle
control, whereas that of FLAG-DYRK1A produced with either
INDY or RD0392 was not (Fig. 4b). This indicates that FINDY
inhibits the incorporation of biotin-ATP into the DYRK1A
intermediate during the folding process. As a positive control,
treatment of the immunopuriﬁed FLAG-DYRK1A with 100 mM
ATP before incubation with the biotin-ATP analogue blocked
biotinylation (Fig. 4b).
Ser97 autophosphorylation in in vitro translation. To conﬁrm
the effect of FINDY on Ser97 autophosphorylation of DYRK1A in
a simpler assay than living cells, we employed an Escherichia coli-
based coupled in vitro transcription-translation system. The
PURExpress system is reconstituted from recombinant proteins
and puriﬁed ribosomes. The signal of p-Ser97 of DYRK1A was
detected when expressed in the PURExpress system (Fig. 5a),
indicating a possibility that Ser97 autophosphorylation does not
require mammalian proteins. The band of p-Ser97 migrated
slower than the major band of the FLAG-DYRK1A protein
(Fig. 5a), indicating that a small portion of DYRK1A is autop-
hosphorylated in this experiment. This suggests a low probability
of the Ser97 autophosphorylation in the in vitro translation. We
then performed the in vitro translation in the presence of FINDY
or RD0392. FINDY and RD0392 suppressed Ser97 autopho-
sphorylation in similar dosage ranges (Fig. 5b–d). In addition,
FINDY did not inhibit substrate phosphorylation by the
DYRK1A protein produced in the PURExpress system (Fig. 5e).
In contrast, RD0392 inhibited substrate phosphorylation in a
dose-dependent manner (Fig. 5e). We also examined tyrosine
autophosphorylation of DYRK1A. In the PURExpress system, no
signiﬁcant effects of FINDY or RD0392 were observed on the
signal from phosphorylated tyrosine (Supplementary Fig. 8).
These results indicate that FINDY suppresses Ser97 autopho-
sphorylation during the in vitro expression of DYRK1A.
We also conﬁrmed whether the mature DYRK1A catalysed
Ser97 autophosphorylation or not using the FLAG-DYRK1A
protein produced in the PURExpress system. Immunopuriﬁed
FLAG-DYRK1A bound on resin was reacted with lambda protein
phosphatase, then allowed to autophosphorylate in the presence
of ATP for 2 h. Consistent with the results using FLAG-DYRK1A
puriﬁed from HEK293 cells (Supplementary Fig. 7d,e), the
puriﬁed DYRK1A protein did not catalyse Ser97 autopho-
sphorylation (Fig. 5f). Thus, Ser97 autophosphorylation is a
one-off event during the translation or folding process. These
results demonstrate that FINDY suppressed Ser97 autopho-
sphorylation before the maturation of DYRK1A.
Ser97 autophosphorylation of recombinant DYRK1A proteins.
To determine whether FINDY directly inhibits Ser97 autopho-


































































































Figure 3 | FINDY suppresses autophosphorylation of Ser97 in DYRK1A. (a) The bicistronic expression of intact DYRK1A (WT) and the substituted
mutants of Lys188 to Arg (K188R), Ser97 to Ala (S97A), Tyr111 to Phe (Y111F), Tyr319 to Phe (Y319F), Tyr321 to Phe (Y321F), Tyr319 and Tyr321 to Phe
(Y319F/Y321F) and Ser529 to Ala (S529A) with EGFP in HEK293 cells. The expression vectors were stably integrated in the genome of the cells. Each
protein was detected with the corresponding antibody against FLAG, EGFP or GAPDH. Representative data from the quadruplicate experiments are shown.
(b) The alignment of Ser97 and its surrounding amino-acid sequences from DYRK1A of the indicated species. The conserved serine residues corresponding
to Ser97 of Homo sapiens DYRK1A are highlighted by the red rectangular box. Underlined portions indicate the phospho-peptide used in the immunization.
(c) The polyclonal antibody against phosphorylated Ser97 (p-Ser97) speciﬁcally detected FLAG-DYRK1A (WT), but not the kinase-dead (K188R) or S97A
mutants. The cells were transiently transfected with the expression vectors of the indicated constructs and the proteins were overexpressed. Total cell
lysates were subjected to SDS–PAGE followed by western blot analysis. Representative data from the triplicate experiments are shown. (d) FINDY
suppressed Ser97 autophosphorylation. FLAG-DYRK1A was produced in HEK293 cells incubated with epoxomicin and FINDY for 5 h, then puriﬁed with
anti-FLAG antibody-conjugated beads. Each protein was detected with the corresponding antibodies against p-Ser97, phospho-Tyr (p-Tyr) or FLAG.
Representative data from the triplicate experiments are shown. (e) FINDY did not suppress Ser97 autophosphorylation in Tc 2. FLAG-DYRK1A was
produced in HEK293 cells for 16 h in the presence of doxycycline, after which cells were treated with 10mM of FINDYor RD0392 for 5 h. Total cell lysates
were subjected to immunoprecipitation (IP) with anti-FLAG antibody-conjugated beads. Each protein was detected with the corresponding antibodies
against p-Ser97 and FLAG. Representative data from the duplicate experiments are shown. Conc., concentration.
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using a recombinant DYRK1A protein. DYRK1A fused with a
GST-tag at the amino-terminus and with a Twin-Strep-tag (TS) at
the carboxy-terminus (GST-DYRK1A-TS) was produced in
E. coli cells at 6 C to suppress autophosphorylation, as we found
that the p-Ser97 signal decreased in cells cultured at low tem-
perature (Supplementary Fig. 9a). GST-DYRK1A-TS was puriﬁed
using tandem afﬁnity puriﬁcation with Strep-Tactin Sepharose
followed by GSH-conjugating resin (Supplementary Fig. 9b), then
subjected to an in vitro reaction with ATP (100 mM). Under these
conditions, the p-Ser97 signal did not increase, whereas the
protein band was broadly shifted (Fig. 6a,b). Therefore, we
wondered if the incubation at 6 C suppressed prior autopho-
sphorylation of the tyrosine residues (Tyr319 and Tyr321) in the
activation loop, which are required for Ser97 autopho-
sphorylation (Supplementary Fig. 9c). To verify this possibility,
we generated pseudo-phosphorylation mutants, in which these
tyrosine residues were substituted for phosphomimetic aspartic or
glutamic acid residues (Y319D, Y319E, Y321D and Y321E), then
examined their facilitation of Ser97 autophosphorylation. The
Y319D and Y319E mutants were puriﬁed (Supplementary
Fig. 9d), whereas the Y321D and Y321E mutants formed aggre-
gates. As expected, the Y319D and Y319E mutations facilitated
Ser97 autophosphorylation of recombinant GST-DYRK1A-TS
(Fig. 6a,b). Furthermore, the Y319E mutant catalysed substrate
phosphorylation at an equivalent level to the WT kinase
(Supplementary Fig. 9e).
We then examined the effect of FINDY on in vitro Ser97
autophosphorylation using the Y319E mutant. FINDY inhibited
Ser97 autophosphorylation with an IC50 value of 110 nM, but did
not suppress tyrosine phosphorylation (Fig. 6c,d), which is
consistent with results in Fig. 3d. The FINDY-mediated inhibition
of Ser97 autophosphorylation decreased due to competition with
excess ATP (1mM; Fig. 6d and Supplementary Fig. 9e). In
contrast, the canonical inhibitor RD0392 suppressed both Ser97
and tyrosine phosphorylation in the Y319E mutant (Fig. 6e,f),
with IC50 values of 205 and 514 nM, respectively. These results
demonstrate that FINDY directly and selectively inhibits Ser97
autophosphorylation.
In addition, we examined whether or not FINDY inhibited
substrate phosphorylation by these recombinant proteins. The
in vitro kinase assay showed that FINDY did not inhibit substrate
phosphorylation by the WT and Y319E proteins in concentra-
tions of up to 16 mM (Fig. 6g). In contrast, RD0392 inhibited
substrate phosphorylation by the WT and Y319E proteins with
IC50 values of 325 and 813 nM, respectively (Fig. 6g).
FINDY strengthens interaction between DYRK1A and CDC37.
Our recent study indicated that mutations affecting autopho-
sphorylation strengthen the interaction between DYRK1A and
the kinase-speciﬁc co-chaperone CDC37 (ref. 36). CDC37 assists
in the folding of target kinases in cooperation with HSP90 (refs
37,38). Taipale et al. have demonstrated that CDC37/HSP90 is
associated with thermodynamically unstable kinases39 and that
CDC37 fused with luciferase acts as a thermodynamic sensor for
kinase structures40.
To investigate whether the mutation of Ser97 affects the
thermodynamic stability of DYRK1A, we examined the interac-
tion between the S97A mutant and CDC37 fused with luciferase
nanoKAZ, as described in our recent study36, with some
modiﬁcations (see the Methods for details). The S97A, Y321F,
Y319F/Y321F and K188R mutations signiﬁcantly strengthened
the interaction of DYRK1A with CDC37-nanoKAZ (Fig. 7a). The
S97A mutant interacted with CDC37-nanoKAZ 2.2-fold more
strongly than intact DYRK1A (Fig. 7a). The Y321F, Y319F/Y321F
and K188R mutants interacted 5.2-, 6.2- and 54-fold more
strongly than intact DYRK1A, respectively (Fig. 7a). Interestingly,
the Y321F mutation increased the interaction (Fig. 7a), but did
not destabilize the DYRK1A protein in HEK293 cells (Fig. 3a).
Thus, the increased interaction with CDC37 is not always
correlated with the degradation of DYRK1A mutants. Therefore,
another functional role of Ser97 may be involved in the
degradation of DYRK1A.
We next investigated whether FINDY decreases the thermo-
dynamic stability of DYRK1A. Treatment with FINDY signiﬁ-
cantly strengthened CDC37-nanoKAZ interactions in a dose-
dependent manner, whereas treatment with RD0392 weakened
the interactions (Fig. 7b), suggesting that FINDY induces
thermodynamic destabilization of DYRK1A. In addition, we
examined the effect of FINDY on the S97A mutant. FINDY also
increased the CDC37 interaction with the S97A mutant, but it
tended to be less than that with intact DYRK1A (Supplementary
Fig. 10). These results suggest that FINDY affected a part of the
folding process in a mechanism independent of the Ser97
autophosphorylation.
Selective inhibition of DYRK1A by FINDY. To determine the
selectivity of FINDY, potential inhibitory activity was assessed
against a panel of 275 kinases using 10 mM of FINDY. Only ﬁve
other kinases (GSK3b, MARK4, PIM1, PIM3, PLK3) were
inhibited by over 75% and none of these showed over 85%
inhibition (Supplementary Table 1). In addition, FINDY did not
exhibit any inhibitory effect on DYRK1B and DYRK2 in an
in vitro kinase assay, whereas RD0392 inhibited both kinases in a
dose-dependent manner (Fig. 8a,b). DYRK1B, the member of the
DYRK family closest to DYRK1A, possesses a conserved serine
residue similar to Ser97 of DYRK1A (Supplementary Fig. 11a),
the mutation of which also leads to destabilization of DYRK1B































Figure 4 | FINDY affects the folding of DYRK1A, targeting the
ATP-binding pocket. (a) Schematic diagram of the biotin-transfer
experiment. Expression of FLAG-DYRK1A is induced by doxycycline (Dox)
with epoxomicin (Epo) and kinase inhibitors (10 mM). The resulting FLAG-
DYRK1A proteins are immunopuriﬁed and reacted with the biotinylated acyl
phosphate of ATP (20 mM). If the inhibitor occupies the ATP-binding
pocket, then biotin transfer is prevented. (b) FINDY competes with the
biotin-ATP analogue for the DYRK1A intermediate. FINDY, INDY and
RD0392 were used as described in a. As a positive control for the
competition experiment, the FLAG-DYRK1A protein was pre-treated with
ATP (100mM) before the reaction with the biotin-ATP analogue. The
labelled proteins were blotted with streptavidin and anti-FLAG antibody.
Representative data from the triplicate experiments are shown. IP,
immunoprecipitation.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11391
6 NATURE COMMUNICATIONS | 7:11391 | DOI: 10.1038/ncomms11391 | www.nature.com/naturecommunications
FINDY destabilizes DYRK1B and DYRK2 in cells expressing
FLAG-DYRK1B-2A-EGFP and FLAG-DYRK2-2A-EGFP,
respectively. Neither the expression of FLAG-DYRK1B nor
FLAG-DYRK2 was affected by FINDY (Fig. 8c,d). These results
suggest that the transitional intermediate of DYRK1A has a
unique structural property distinct from that of DYRK1B and
DYRK2. Moreover, FINDY decreased the amount of endogenous
DYRK1A in HEK293 cells, whereas no alteration in the endo-
genous expression of the other 13 kinases was observed (Fig. 8e),
indicating that FINDY selectively destabilizes the transitional
intermediate of DYRK1A.
We have previously reported that microinjection of DYRK1A
mRNA into Xenopus laevis embryos causes the malformation of
neural tissues, and this system has been applied to assess the
efﬁcacy of kinase inhibitors in vivo16. To validate the subtype-
selectivity of FINDY in the context of living organisms, we
investigated whether FINDY rescues the developmental
malformation of Xenopus embryos induced by the
overexpression of DYRK1A or DYRK1B. DYRK1A or DYRK1B
mRNA was injected into two dorsal blastomeres at the eight-cell
stage, resulting in malformation of the eye and the head in stage
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Figure 5 | FINDYsuppresses Ser97 autophosphorylation of DYRK1A in an in vitro transcription-translation system. (a) Expression of DYRK1A in a cell-
free E. coli-based coupled transcription-translation system. Representative data from the duplicate experiments are shown. (b,c) In vitro expression of
DYRK1A in the presence of FINDY (b) or RD0392 (c). Representative data from the triplicate experiments are shown. (d) Relative activities of Ser97
autophosphorylation in the in vitro expression of DYRK1A in the presence of FINDYor RD0392. The band intensities in b,c were quantiﬁed. The graph shows
the means±s.d. (n¼ 3). (e) DYRK1A produced in the in vitro system was incubated with the peptide substrate DYRKtide in the presence of FINDY or
RD0392 (up to 32mM). The results are presented as means±s.d. (n¼ 3). (f) DYRK1A produced in the in vitro system was puriﬁed with anti-FLAG
antibody-conjugated beads, then reacted with lambda protein phosphatase for 2 h. After washout of phosphatase, the dephosphorylated DYRK1A was
allowed to autophosphorylate in the presence of ATP and sodium orthovanadate (1mM) for 2 h. To check the residual phosphatase activity, the non-treated
FLAG-DYRK1A protein was added into the autophosphorylation reaction (lane 5). Representative data from the duplicate experiments are shown. Conc.,
concentration.
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morphological alterations compared with uninjected embryos
(Fig. 9a). Administration of proINDY, which is an acetylated
prodrug with enhanced cell membrane permeability hydrolysed
in the cell to form INDY16, repressed the malformation induced
by both DYRK1A and DYRK1B (Fig. 9a). FINDY rescued the
malformation induced by DYRK1A, but not that induced by
DYRK1B, demonstrating marked subtype-selectivity (Fig. 9a).
Embryos injected with DYRK1A mRNA were almost completely
rescued with the administration of either FINDY or proINDY
(Fig. 9b). Only 10.9% of the tadpoles developed normally with
FINDY when injected with DYRK1B mRNA, whereas 89.1% were
normal in the presence of proINDY (Fig. 9b). In the embryos
injected with either DYRK1A or DYRK1B mRNA, decreased
expression of the pan-neural marker NCAM, forebrain marker
BF-1, eye markers Pax-6 and Rx-1, fore-midbrain marker Otx-2,
mid-hindbrain marker En-2 and hindbrain marker Krox-20 were
observed (Fig. 9c). FINDY restored the expression of these
markers only in DYRK1A-overexpressing tadpoles, whereas
proINDY increased the expression of the markers in both
DYRK1A- and DYRK1B-overexpressing embryos (Fig. 9c). These
results indicate that FINDY rescues the neurological defects
induced by DYRK1A in a highly speciﬁc manner.
Discussion
This study provides methods for evaluating chemical compounds
that selectively inhibit the transitional intermediates of target
kinases. We utilized these methods to identify and evaluate
FINDY. Based on the following evidence, we demonstrate that
FINDY selectively inhibits a folding intermediate of DYRK1A
during its folding process, as illustrated in Fig. 10. First, FINDY
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Figure 6 | FINDY inhibits Ser97 autophosphorylation of recombinant DYRK1A protein. (a) Recombinant GST-DYRK1A-TS protein (WT) and its pseudo-
phosphorylation mutants (Y319D and Y319E), produced at 6 C in E. coli, were reacted with ATP (100mM), then analysed by SDS–PAGE followed by
western blot analysis. Representative data from the quadruplicate experiments are shown. (b) The band intensities in a were quantiﬁed. The graph shows
the means±s.d. (n¼4). Statistical signiﬁcance was calculated compared with the value without ATP. NS indicates not signiﬁcant. *Po0.05. Statistical
analysis was performed with the Mann–Whitney U-test. (c) The Y319E mutant was reacted with ATP (100mM) in the presence of FINDY. Representative
data from the triplicate experiments are shown. (d) Relative activities of Ser97 and tyrosine phosphorylation in the presence of ATP (100mM and 1mM)
and FINDY, which were calculated from the ATP-dependent increase in the intensities of p-Ser97 and p-Tyr (see the Methods for details). The graph
represents means±s.d. (n¼ 3). Statistical signiﬁcance was calculated compared with the value of the relative activity of p-Tyr at the same concentration of
FINDY. *Po0.05 and **Po0.01. Data were analysed with the paired t-test. (e) RD0392 inhibited the phosphorylation of Ser97 and tyrosine residues. The
Y319E mutant was reacted with ATP (100mM) in the presence of RD0392. Representative data from the triplicate experiments are shown. (f) Relative
activities of Ser97 and tyrosine phosphorylation in the presence of ATP (100mM) and RD0392, which were calculated from the ATP-dependent increase in
the intensities of p-Ser97 and p-Tyr (see the Methods for details). The graph represents means±s.d. (n¼ 3). (g) The recombinant DYRK1A proteins were
incubated with the peptide substrate DYRKtide in the presence of FINDY or RD0392 (up to 16 mM). The results are presented as means±s.d. (n¼ 3).
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it is administered before the induced expression (Fig. 1c). Second,
neither in the cell-based nor in the in vitro assays is FINDY able
to inhibit the substrate phosphorylation by the mature DYRK1A
(Figs 1c,f, 5e and 6g). Third, FINDY suppressed Ser97 autopho-
sphorylation in cells (Fig. 3d), in the in vitro translation (Fig. 5),
and in the in vitro autophosphorylation assay with the
recombinant protein (Fig. 6). The Ser97 autophosphorylation
was a one-off intramolecular process that was not catalysed by the
mature DYRK1A (Fig. 5f and Supplementary Fig. 7d,e). Further-
more, the CDC37-nanoKAZ interaction assay revealed that
FINDY induces the thermodynamic destabilization of DYRK1A
(Fig. 7b), suggesting that FINDY affects the folding state of
DYRK1A.
Our study demonstrates that FINDY directly suppresses Ser97
autophosphorylation, as discussed below. First, FINDY sup-
pressed Ser97 autophosphorylation in the in vitro translation
system (Fig. 5), which contained only deﬁned factors, but did not
contain mammalian proteins. Second, FINDY suppressed the
in vitro Ser97 autophosphorylation of the recombinant phospho-
mimetic mutant (Y319E) of DYRK1A, whereas tyrosine autopho-
sphorylation was not suppressed by FINDY (Fig. 6 and
Supplementary Fig. 5). These results are consistent with the
results from the cellular assays (Fig. 3d). Several lines of evidence
demonstrated that the mature DYRK1A was not able to catalyse
Ser97 autophosphorylation (Figs 5f and 6a,b and Supplementary
Fig. 7d,e). Thus, the kinase form that catalyses Ser97 autopho-
sphorylation is not the mature form. Therefore, the recombinant
Y319E probably reﬂects an aspect of the folding intermediate.
Third, FINDY blocked the incorporation of biotin-ATP into
DYRK1A (Fig. 4), indicating two possibilities. One is that FINDY
occupies the ATP-binding pocket. The other is that FINDY
affects the biotin-ATP incorporation by binding to an allosteric
site, which may affect the ATP binding to the pocket. FINDY
possesses the same polar groups of RD0392 that targets the ATP-
binding pocket of DYRK1A (Supplementary Figs 2 and 3). Thus,
the former scenario is most likely. The selectivity of FINDY for
the Ser97 and tyrosine autophosphorylation suggests that the
transitional state targeted by FINDY is distinct to that of tyrosine
autophosphorylation. Further structural studies are necessary to
conclude this discussion.
The phosphomimetics experiment suggested that the phos-
phorylated tyrosine residue in the activation loop is required for
the subsequent Ser97 autophosphorylation (Fig. 6). Although
intramolecular tyrosine autophosphorylation in the activation
loop has been suggested to be a one-off inceptive event to achieve
full activity during the co-translational folding process of
Drosophila DYRKs17,19,41, it is controversial whether the
autophosphorylation of these tyrosine residues is essential for
the catalytic activity of mammalian DYRK1A21,33. The double
mutation of Y321F/Y319F in the activation loop destabilized
FLAG-DYRK1A, whereas a single mutation gave a much smaller
effect (Fig. 3a). Our study indicates that the autophosphorylation
of at least one of these tyrosine residues is required for Ser97
autophosphorylation, suggesting that Ser97 autophosphorylation
acts as a quality control mechanism. It remains elusive how Ser97
autophosphorylation regulates the stability of DYRK1A and why
Ser97 autophosphorylation is a one-off process. In comparison to
the in vitro translation (Fig. 5a), we did not observe the faster
migrating band corresponding to the Ser97 non-phosphorylated
DYRK1A in the cultured mammalian cells, which may be
subjected to degradation during the folding process. The actual
amount of the Ser97 autophosphorylation during the folding
process in mammalian cells also remains unclear.
Although RD0392 inhibited the Ser97 autophosphorylation in
the in vitro translation experiment (Fig. 5c,d) and in the
autophosphorylation assay using the recombinant DYRK1A
protein (Fig. 6e,f), RD0392 did not decrease the FLAG-DYRK1A
protein in the cultured cells (Fig. 2d). This discrepancy is possibly
due to low cell membrane permeability of RD0392. FINDY has a
hydrophobic trimethylsilyl group that may serve to enhance the
cell membrane permeability compared with that of RD0392.
RD0392 inhibited the Tyr autophosphorylation of the recombi-
nant DYRK1A protein (Fig. 6e,f). In contrast, RD0392 did not
inhibit the Tyr autophosphorylation in the in vitro translation
(Supplementary Fig. 8c). This indicates the possibility that
RD0392 is capable of inhibiting post-translational Tyr autopho-
sphorylation, but co-translational Tyr autophosphorylation is
resistant to RD0392.
An interesting point in the biotin-ATP experiment is that
INDY and RD0392 failed to inhibit biotinylation, whereas
FINDY, on the other hand, did not (Fig. 4b). The most likely
explanation is that FINDY has a slower rate of dissociation (Koff)
from the intermediate of DYRK1A than the Koffs that INDY and
RD0392 have to the mature form. This slow Koff for FINDY may
be due to thermodynamic destabilization by FINDY, which is
distinct from the effects of INDY and RD0392. FINDY uniquely
strengthened the interaction between DYRK1A and CDC37-
nanoKAZ (Fig. 7b). In contrast, RD0392 and INDY weakened the
interaction (Fig. 7b)36, which is in good agreement with previous
reports that canonical kinase inhibitors weaken CDC37
interactions39,40,42. A previous study has demonstrated that
CDC37 binding competes with ATP for the pocket of its client
kinase42, suggesting that the enhanced binding of CDC37 plays a
role in the suppression of the biotinylation. Furthermore, the
thermodynamic destabilization caused by FINDY may also cause
hydrophobic aggregation of the DYRK1A protein, which masks














































































Figure 7 | FINDY strengthens the interaction between DYRK1A and the
co-chaperone CDC37. (a) 293T cells stably expressing CDC37-nanoKAZ
were transiently transfected with expression vectors of 3xFLAG-DYRK1A,
as were mutants of S97A, Y319F, Y321F, Y319F/Y321F and K188R. Total cell
lysates were subjected to the CDC37-nanoKAZ interaction assay (see the
Methods for details). Luminescence intensities are shown as fold-changes
relative to that of DYRK1A, normalized to the amount of bound protein on a
96-well plate. The graphs represent means±s.d. (n¼ 7). Statistical
signiﬁcance was calculated compared with the value of the intact DYRK1A.
***Po0.001. Statistical analysis was performed with the Mann–Whitney
U-test. (b) 293T cells stably expressing CDC37-nanoKAZ were transiently
transfected with an expression vector of 3xFLAG-DYRK1A. Twenty-four
hours after the transfection, cells were treated with FINDY and RD0392,
and incubated for an additional 24 h. Luminescence intensities are shown as
fold-changes relative to that at 0mM, normalized to the amount of 3xFLAG-
DYRK1A bound on a 96-well plate. Points on the graph are means±s.d.
(n¼8). Statistical signiﬁcance was calculated compared with the value at
0mM. *Po0.05, **Po0.005 and ***Po0.001. Statistical analysis was
performed with the Mann–Whitney U-test.
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consider that thermodynamic destabilization by FINDY may
result in strong competition with the biotin-ATP.
The SPHINKS assay consists of cells expressing DYRK1A and
its substrate fused with a DD tag and the detection of TAU
phosphorylation. This assay was developed to evaluate the effect
of chemical compounds on the folding process of DYRK1A;
however, it is not suitable for high-throughput screening of large-
scale chemical libraries. Thus, the SPHINKS assay should be
utilized as a second or third screening assay for a small number of
chemical compounds that were roughly selected from the library
by a robust high-throughput assay. The in vitro translation and
autophosphorylation assays would be better methods for devel-
oping high-throughput assays. Some small molecules may show
apparent selectivity in the SPHINKS assay because of slower
actions, such as low solubility, pro-drug activation or slow uptake
into cells. Thus, the properties of small molecules should be
carefully examined.
This study demonstrates that targeting transitional intermedi-
ates is a promising strategy for the development of novel kinase
inhibitors. Intramolecular autophosphorylation in the activation
loop has been demonstrated not only in DYRK1A, but also in
other kinases, such as DYRK2 (ref. 19), GSK3b (ref. 18), ERKs43
and the Parkinson’s disease-associated kinase LRRK2 (refs 44,45).
In addition, autophosphorylation outside the activation loop has
been reported in C-RAF46 and protein kinase A (PKA)47. We
believe that intermediate-selective inhibitors for these kinases can
be identiﬁed. The close structural similarity between the
intermediate-selective inhibitors and the canonical inhibitors
raises the possibility that canonical ATP-competitive kinase
inhibitors can be converted to intermediate-selective inhibitors
with only a slight modiﬁcation of the common chemical scaffold
(Supplementary Figs 12 and 13). Numerous compounds targeting
various kinases have been rejected in in silico or in vitro drug
screening, but some could potentially inhibit a transitional
intermediate of the target kinase. The methods developed in
this study can be utilized to reassess these compounds and
provide opportunities to rediscover selective kinase inhibitors.
The dynamic state of the transitional intermediate may provide
conformational diversity for the inhibitor-binding pocket. It is
possible to purify the metastable intermediate of the DYRK1A
protein produced in the presence of FINDY, as we have
preliminarily tried in Figs 4 and 5. Further studies using
biophysical techniques are necessary in order to analyse the
intermediate state targeted by FINDY. Resolving the intermediate
states of kinases would expand the chemical options available for
the design of selective inhibitors.
Methods
Materials. Small molecules were prepared using standard synthetic procedures, as
described in Supplementary Methods. INDY and proINDY were prepared as
described previously16. These compounds were dissolved in dimethylsulphoxide
(DMSO) at 10mM as a stock solution. Calyculin A (Cell Signaling Technology),
okadaic acid (Tocris Bioscience) and cantharidic acid (Abcam) were purchased.
The polyclonal antibody against p-Ser97 was produced by immunizing rabbits with
a synthetic phospho-peptide, C-PEG-PLRKLS*VDLIK, which was coupled to KLH
via the free cysteine, with S* representing phosphoserine. The speciﬁc antibody was
















































































































Figure 8 | FINDY selectively inhibits DYRK1A. (a,b) Recombinant DYRK1B (a) and DYRK2 (b) were incubated with the peptide substrate DYRKtide in the
presence of FINDY, RD0392 or INDY. RD0392 and INDY inhibit the kinase activity with IC50 values of 53.3 and 69.2 nM, respectively, for DYRK1B, and with
IC50 values of 45.6 and 27.7 nM, respectively, for DYRK2. The results are presented as means±s.d. (n¼4). (c,d) Bicistronic expression of FLAG-DYRK1B
(c) and FLAG-DYRK2 (d) with EGFP in HEK293 cells. FINDY administered at the indicated concentrations (Conc.) did not affect the expression of FLAG-
DYRK1B and FLAG-DYRK2. Representative data from the triplicate experiments are shown. (e) Intact HEK293 cells were cultured in the presence of FINDY
for 3 days. The indicated kinases and GAPDH were detected by western blot analysis using the corresponding antibodies. The categories of the indicated
kinases in the kinome are shown. Representative data from the duplicate experiments are shown.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11391
10 NATURE COMMUNICATIONS | 7:11391 | DOI: 10.1038/ncomms11391 | www.nature.com/naturecommunications
column containing non-phospho-peptide. The polyclonal antibody against p-Ser97
(1/2,000) and antibodies listed below were diluted with Can Gel Signal
Immunoreaction Enhancer Solution (TOYOBO) in western blot analysis. Mouse
monoclonal anti-DYKDDDDK (FLAG) tag (1/1,000, clone 1E6, 018-22381/Lot:
CTR5949) and anti-GFP (1/1,000, mFX75, 012-22541/Lot: STK2113) antibodies
were purchased from Wako Pure Chemical Industries, mouse monoclonal anti-HA
(1/1,000, clone HA124, 06340-54/Lot: M2E8170) antibody from Nacalai Tesque,
mouse monoclonal anti-GAPDH (1/10,000, clone 6C5, AM4300/Lot: 1311029)
from Thermo Fisher Scientiﬁc, mouse monoclonal anti-TAU (1/3,000, clone TAU-
5, 577801/Lot: D00100518) from Calbiochem (Merck), rabbit polyclonal antibody
against pT212 of TAU (1/3,000, 44740G/Lot: 1392715A) from Life Technologies,
mouse monoclonal anti-phosphotyrosine (1/3,000, 4G10 Platinum, 05-1050/Lot:
2567063) from Millipore, mouse monoclonal anti-GST-tag (1/3,000, clone GT5,
M209-3/Lot: 001) from MBL, mouse monoclonal anti-SRPK1 (1/3,000, clone 12/
SRPK1, 611072) from BD Transduction Laboratories (BD Biosciences), mouse
monoclonal anti-CDK9 (1/3,000, clone D-7, sc-13130/Lot: c0613) from Santa Cruz
Biotechnology and mouse monoclonal anti-neuronal class III b-Tubulin (1/3,000,
clone TUJ1, MRB-435P/Lot: E10045BF) from Covance. Rabbit polyclonal anti-
DYRK1A (1/3,000, #2771S/Lot: 1), p70S6K (1/3,000, #9202S/Lot: 8), CHK2 (1/
3,000, #2662S/Lot: 5), MARK3 (1/3,000, #9311BC/Lot: 1), RAF1 (1/3,000,
#9422BC/Lot: 5), FAK (1/3,000, #3285BC/Lot: 6), FYN (1/3,000, #4023BC/Lot: 2)
and ABL (1/3,000, #2862BC/Lot: 11) antibodies were obtained from Cell Signaling
Technology. Rabbit monoclonal anti-GSK3b (1/3,000, clone 27C10, #9315S/Lot: 4),
AKT1 (1/3,000, clone C73H10, #2938BC/Lot: 2), MEK1 (1/3,000, clone 30C8,
#9146BC/Lot: 1) and SRC (1/3,000, clone 32G6. #2123BC/Lot: 3) antibodies were
purchased from Cell Signaling Technology. HRP-linked anti-rabbit (1/4,000,
NA9340V/Lot: 9611780) and anti-mouse (1/4,000, ab5887/Lot: GR16899-9) IgG
were purchased from GE Healthcare and Abcam, respectively. HRP-labelled
streptavidin (1/2,000, 474-3000/Lot: 060065) was obtained from Kirkegaard &
Perry Laboratories.
Vector construction. In brief, the bicistronic expression vectors for the DYRKs
were constructed with pcDNA5/FRT/TO (Life Technologies). DD-TAU and DD-
FLAG-DYRK1A were inserted into the pCAGIPuro vector. To prepare in vitro
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Figure 9 | FINDY selectively represses excessive DYRK1A activity in an animal model. (a) FINDY rescued the developmental malformation of Xenopus
laevis embryos as induced by the overexpression of DYRK1A, but did not rescue that induced by DYRK1B. proINDY was effective in both cases. Embryos
were treated with the vehicle alone ( ), FINDY (2.5 mM) or proINDY (2.5mM), then two dorsal blastomeres were injected with 750pg of b-globin, DYRK1A
or DYRK1B mRNA at the eight-cell stage. Uninjected embryos were used as controls. Development of the embryos was allowed to proceed to stage 40 in
the dark. Representative images are shown. Arrows indicate small eyes. (b) Summary of the rescue rates of small eyes as induced by the overexpression of
DYRK1A or DYRK1B. The results are the means±s.e.m. of triplicate experiments (n¼ 55). (c) RT–PCR analysis of the neural marker genes in the head
regions of the embryos at stage 25. Each of the marker genes indicates a speciﬁc region: NCAM for the pan-neural region, Brain Factor-1 (BF-1) for the
forebrain, Pax-6 and Rx-1 for the eye, Otx-2 for the fore-midbrain, Engrailed-2 (En-2) for the mid-hindbrain and Krox-20 for the hindbrain. Ornithine
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Figure 10 | Model of the folding intermediate-selective inhibition by
FINDY. In the folding process of DYRK1A, a folding intermediate
autophosphorylates Tyr319/321 and subsequently Ser97 in an
intramolecular manner, which prevents degradation of DYRK1A.
Autophosphorylated DYRK1A takes on a mature conformation. FINDY
interferes only with the folding intermediate by preventing the
incorporation of ATP, leading to its degradation.
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pCold (Takara Bio) and pET28a(þ ) vectors were used for the preparation of
recombinant protein in E. coli cells. The pET28a(þ ) vector was also used for the
in vitro translation experiments. PCR-ampliﬁed fragments of the human micro-
tubule-associated protein TAU (0N4R) and FLAG-tagged DYRK1A were fused in-
frame to the carboxyl-terminus of DD tag by the overlap-extension PCR method to
generate DD-TAU and DD-FLAG-DYRK1A, respectively, as described pre-
viously48, with some modiﬁcations. The combined fragments were inserted into the
pCAGIPuro vector, an IRES-based bicistronic expression vector where the gene of
interest and a puromycin-resistant gene are expressed from a single mRNA, which
enables almost all of the cells selected with puromycin to express the gene product.
A PCR-ampliﬁed fragment of FLAG-tagged DYRK1A was subcloned into
pcDNA5/FRT/TO. For the bicistronic cassette using a 2A peptide, PCR-ampliﬁed
fragments of FLAG-tagged DYRKs were fused in-frame to the amino-terminus of
EGFP via the F2A peptide sequence by the overlap-extension PCR method. The
combined fragments were inserted into pcDNA5/FRT/TO (Life Technologies). The
site-directed mutagenesis of DYRK1A and DYRK1B was performed as described
previously49, with some modiﬁcations. The reconstituted vector sequences are
available upon request.
Cell culture and transfection. Flp-In/T-REx HEK293 (Life Technologies) and
intact HEK293 cells were maintained in low-glucose DMEM (Nacalai Tesque)
supplemented with 10% fetal bovine serum (FBS; Nichirei Biosciences),
100Uml 1 of penicillin and 100 mgml 1 of streptomycin (Nacalai Tesque). Cells
were transfected with plasmid DNAs using polyethylenimine MAX (Polysciences)
as described previously50, then selected with hygromycin B (Life Technologies) for
the pcDNA5/FRT/TO vectors and/or with puromycin (Nacalai Tesque) for the
pCAGIPuro vectors to establish stable cell lines.
SPHINKS assay. Our original synthetic chemical library used in this study con-
sisted of newly synthesized structural derivatives of ATP-competitive inhibitors of
DYRK1A, which had been identiﬁed by an in vitro kinase assay in our laboratory.
Flp-In/T-REx HEK293 cells transfected with pcDNA5/FRT/TO-FLAG-DYRK1A
and pCAGIPuro-DD-TAU were seeded on polyethylenimine-coated six-well plates
with 2ml of DMEM and 1% FBS. Cells were then cultured 24 h later in the
presence of 1 mgml 1 of doxycycline (Nacalai Tesque) for 16 h, then treated with
1 mM of Shield-1 (Clontech, Takara Bio) for 2 h. Small molecules from our che-
mical library were diluted in 1ml of DMEM and 1% FBS, then administered into
the cells at a ﬁnal concentration of 10 mM (0.1% DMSO), as illustrated in Fig. 1a.
Total cell lysates were prepared with SDS-urea buffer (50mM Tris-HCl, pH 7.0, 1%
SDS, 4M urea, 10% glycerol, 20mM dithiothreitol, 0.5mgml 1 BSA), then ana-
lysed with SDS–polyacrylamide gel electrophoresis (SDS–PAGE) followed by
western blot analysis using antibodies against phospho-TAU (pT212) (1/3,000) and
total TAU (1/3,000) proteins (Supplementary Fig. 14). Details are summarized in
Supplementary Table 2.
Immunoprecipitation of FLAG-DYRK1A. HEK293 cells were cultured in the
presence of 1 mgml 1 of doxycycline, 1 mM of Shield-1, 1 mM of epoxomicin and a
proteasome inhibitor (Peptide Institute), with or without 10 mM of small molecules
for 5 h. The cells were lysed in 50mM Tris (pH 7.4), 150mM NaCl, 0.5mM EDTA,
1% Empigen BB and protease/phosphatase inhibitor cocktails (Nacalai Tesque).
The clariﬁed cell lysates were processed with anti-FLAG (clone M2) beads (F2426,
Sigma-Aldrich) and the bound proteins were then eluted with SDS-urea buffer,
then analysed with SDS–PAGE followed by western blot analysis (Supplementary
Fig. 14).
Biotin transfer experiment. Biotinylation of the lysine in the ATP-binding pocket
was performed using the Pierce Kinase Enrichment Kit with an ATP Probe
(Thermo Fisher Scientiﬁc), according to the manufacturer’s instructions with some
modiﬁcations. HEK293 cells were cultured with 1 mgml 1 of doxycycline and
1 mM of epoxomicin, with or without 10 mM of small molecules for 5 h, then
harvested and lysed in Pierce IP Lysis Buffer containing 0.5% Empigen BB. The
clariﬁed cell lysates were processed with anti-FLAG (M2) beads, then equilibrated
with the kit’s reaction buffer. The beads were subsequently reacted with 20 mM of
the kit’s ActivX Desthiobiotin-ATP probe for 30min at room temperature. The
bound proteins were eluted with SDS-urea buffer, then analysed with SDS–PAGE
followed by western blot analysis (Supplementary Fig. 14).
E. coli-based in vitro translation assay. The PURExpress kit (New England
Biolabs) was employed. DYRK1A was expressed at 37 C for 40min in a 12.5-ml
reaction mixture containing 30 ng of pET28a(þ )-FLAG-DYRK1A. For inhibitor
experiments, FINDY or RD0392 was added prior to the initiation of transcription.
For immunoprecipitation, 100ml of PBS containing 0.5% Empigen BB,
0.5mgml 1 BSA and 5mM EDTA was added into the reaction mixture, then
incubated with anti-FLAG (M2) beads at 4 C for 6 h. The samples were prepared
with an SDS-urea buffer, then analysed with SDS–PAGE followed by western blot
(Supplementary Fig. 14). The band intensities were measured using the LAS-3000
(Fujiﬁlm) and Multi Gauge software (Fujiﬁlm).
For the phosphatase experiment, immunoprecipitated FLAG-DYRK1A bound
on the beads was incubated in a total volume of 100 ml containing 1,600U of
lambda protein phosphatase for 2 h at 30 C. After washing the beads with
autophosphorylation reaction (AR) buffer (see below) containing 0.1mgml 1 of
BSA (Sigma-Aldrich), the beads were incubated with the indicated concentrations
of ATP and sodium orthovanadate (1mM) for 2 h at 37 C and prepared with the
SDS-urea buffer. To check the residual phosphatase activity, non-treated
immunoprecipitated FLAG-DYRK1A bound on the beads was added into the
reaction.
For the in vitro kinase assay, 0.5 ml of the reaction mixture was incubated in a
total volume of 25 ml of AR buffer containing 0.1mgml 1 of BSA, 100mM of ATP,
50 mM of DYRKtide peptide (Anaspec) and the indicated concentrations of the
small molecules for 2 h at 37 C. The consumption of ATP was measured with
ADP-Glo Kinase Assay kit (Promega Corporation).
In vitro autophosphorylation assays. E. coli strain Rosetta(DE3)pLysS was
transformed with the pCold-I-GST-DYRK1A-TS vector. The cells were cultured
with IPTG (ﬁnal 1mM) for 24 h at 6 C, then lysed with GET buffer (20mM
HEPES-KOH, pH 8.0, 150mM NaCl, 1mM EDTA, 2mM dithiothreitol, 10%
glycerol, 0.5% Empigen BB, 0.5% Triton X-100). Clariﬁed cell lysates were loaded
onto a Strep-Tactin Sepharose column (IBA) and the bound proteins were then
eluted with GET buffer containing 2.5mM desthiobiotin (IBA) and 1mgml 1
BSA. The eluates were subsequently applied to GST-Accept resin (Nacalai Tesque).
The resin was washed extensively, ﬁrst with GET buffer, then with AR buffer
(5mM MOPS, pH7.2, 2.5mM b-glycerol-phosphate, 5mM MgCl2, 1mM EGTA,
0.4mM EDTA, 2mM tris(2-carboxyethyl)phosphine). The GST-DYRK1A-TS
(0.5 pmol) bound on the resin (bed vol. 2 ml) was suspended in 100 ml of AR buffer,
mixed with 1 ml of a stock DMSO solution of FINDY or RD0392, then incubated at
37 C for 30min. We then added 5 ml of 2mgml 1 BSA to the suspension (ﬁnal
concentration of 0.1mgml 1), followed by incubation at 37 C for 30min. We
then added 5 ml of ATP solution to the suspension (ﬁnal concentrations of 100mM
and 1mM), which was subsequently incubated at 37 C for 2 h. The bound proteins
were eluted with SDS-urea buffer, then analysed with SDS–PAGE followed by
western blot (Supplementary Fig. 14).
The band intensities were measured using the ChemiDoc MP Imaging System
(Bio-Rad). In Fig. 6d,e, the relative activity of the phosphorylation was calculated
from the ATP-dependent increase in the intensity of the p-Ser97 and p-Tyr signals
by subtracting the band intensity in the absence of ATP from that in the presence
of ATP.
For the in vitro kinase assay, 2 ml (bed vol.) of the resin was incubated in a total
volume of 25ml of AR buffer containing 0.1mgml 1 of BSA, 100 mM of ATP,
50 mM of DYRKtide peptide and the indicated concentrations of the small
molecules, for 2 h at 37 C. The consumption of ATP was measured with ADP-Glo
Kinase Assay kit.
CDC37-nanoKAZ interaction assay. The CDC37-nanoKAZ interaction assay was
performed as described previously36, with some modiﬁcations. 293T cells stably
expressing CDC37-nanoKAZ were transiently transfected with the expression
vector 3xFLAG-DYRK1A, then cultured in a 96-well plate. Twenty-four hours after
the transfection, FINDY and RD0392 were added to the wells at the indicated
concentrations and the cells were cultured for an additional 24 h. The cells were
lysed in ice-cold HENG buffer (50mM HEPES-KOH, pH 7.9, 150mM NaCl,
20mM Na2MoO4, 2mM EDTA, 5% glycerol, 0.5% Triton X-100) containing
protease inhibitor cocktail (Nacalai Tesque) on ice. The cleared lysates were added
to 96-well plates (OptiPlate-96 HB; Perkin Elmer) coated with antibody against
FLAG peptide (clone M2, F3165/Lot: SLBH1191V) diluted in sodium bicarbonate
buffer (pH 9.6), and incubated at 4 C for 3 h. The wells were wash three times with
ice-cold HENG buffer and then a luminescence assay was performed. The
luminescence of the captured CDC37-nanoKAZ was measured using the Centro
LB 960 Microplate Luminometer (Berthold Technologies). A reaction mixture
containing bis-coelenterazine (ﬁnal concentration of 0.1–1mg in 100 ml) in PBS
containing 0.02% Tween-20 and 20mM EDTA was injected. The luminescence
intensity was recorded at 0.1 s intervals for 10 s or 10min. The maximum
luminescence intensity (Imax), represented in relative luminescence units, was used
in the study. The captured 3xFLAG-DYRK1A was also measured using HRP-
conjugated anti-FLAG antibody (clone M2, A8592/Lot: SLBH1183V, Sigma-
Aldrich) and TMD Super Sensitive One Component HRP Microwell Substrate
(SurModics, Eden Prairie). The relative amount of protein bound on the well was
estimated from the absorbance. The relative luminescence intensities were
normalized to the amount of captured 3xFLAG-DYRK1A, and calculated as the
fold-change relative to the value at 0 mM of the compounds.
Handling of Xenopus laevis embryos and reverse transcription (RT)–PCR
analysis. DYRK1A and DYRK1B mRNA, which were synthesized from linearized
vectors with the mMessage mMachine Kit (Life Technologies), were injected into
two dorsal blastomeres at the eight-cell-stage for RT–PCR analysis and observation
of the embryo phenotypes. Solutions containing proINDY or FINDY (2.5 mM each)
were used to treat the embryos just after fertilization. The head regions of the
injected embryos were dissected at the neural stage (stage 25) and the total RNA
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was isolated using TRIzol (Life Technologies). cDNA synthesis was carried out
using Moloney murine leukaemia virus reverse transcriptase (Life Technologies).
The sequences of the primer pairs were as follows51,52: NCAM, 50-GCGGGTACCT
TCTAATAGTCAC-30 and 50-GGCTTGGCTGTGGTTCTGAAGG-30 ; Brain factor
1 (BF-1), 50-TCAACAGCCTAATGCCTGAAGC-30 and 50-GCCGTCCACTTTCT
TATCGTCG-30 ; Pax-6, 50-CAGAACATCTTTTACCCAGGA-30 and 50-ACTACT
GCTAATGGGAATGTG-30 ; Rx1, 50-CCCCAACAGGAGCATTTAGAAGAC-30
and 50-AGGGCACTCATGGCAGAAGGTT-30 ; Otx-2, 50-GGATGGATTTGTTGC
ACCAGTC-30 and 50-CACTCTCCGAGCTCACTTCTC-30; En-2, 50-CGGAATTC
ATCAGGTCCGAGATC-30 and 50-GCGGATCCTTTGAAGTGGTCGCG-30 0 ;
Krox-20, 50-AACCGCCCCAGTAAGACC-30 and 50-GTGTCAGCCTGTCCTGTT
AG-30 ; ornithine decarboxylase (ODC), 50-GTCAATGATGGAGTGTATGGA
TC-30 and 50-TCCATTCCGCTCTCCTGAGCAC-30 . No randomization was used,
and no blinding was done.
Mass spectrometry. HEK293 cells were cultured in the presence of 1 mgml 1
doxycycline and 1 mM epoxomicin, with or without 10 mM FINDY for 8 h. The cells
were then harvested and lysed in 50mM Tris (pH 7.4), 150mM NaCl, 0.5mM
EDTA, 1% Empigen BB and protease/phosphatase inhibitor cocktails (Nacalai
Tesque). The clariﬁed cell lysates were processed with anti-FLAG (M2) beads
(Sigma-Aldrich) and the bound proteins were then eluted with glycine buffer (pH
3.0), which was immediately neutralized with 1M Tris (pH 8.0). After reductive
alkylation, the samples were trypsinized, then processed using ZipTip pipette tips
containing C18 (Millipore). The digested and puriﬁed peptides were analysed by
LC-MS/MS on TripleTOF 5600 (AB SCIEX). Database searches were performed
using ProteinPilot Software (AB SCIEX).
RI-In vitro kinase assay. The RI-in vitro kinase assay was performed as described
previously16,53, with some modiﬁcations. His-tagged human DYRK1A kinase
domain (residues 127–485) was produced in E. coli then puriﬁed with Ni-NTA.
GST-tagged full-length human DYRK1B recombinant proteins and His-tagged
full-length human DYRK2 recombinant proteins were obtained from Life
Technologies and Millipore, respectively. The kinase reaction was performed in a
reaction mixture containing serially diluted inhibitors, 10mM MOPS-KOH (pH
7.0), 10mM magnesium acetate, 200mM EDTA, 1 mM ATP, 0.1–0.4 mCi
[g-32P]ATP, 5 mM DYRKtide and 0.1–1 mg recombinant kinase, for a ﬁnal volume
of 25 ml. The ﬁnal concentration of DMSO was adjusted to 1%, regardless of the
inhibitor concentration. The reaction mixture was incubated at 30 C for 10min
and phosphoric acid (ﬁnal 5%) was then added to stop the reaction. We then
dispensed 25ml of the reaction mixture onto P81, a phosphocellulose membrane
(Whatman, GE Healthcare), and washed four times in 5% phosphoric acid.
Cherenkov light from the incorporated 32P was measured using a liquid
scintillation counter. The kinase assay conditions, including the incubation period
and the concentration of the kinases and substrates, were optimized to maintain
linearity during the incubation. The net radioactivity was determined by
subtracting the background count from the reaction mixture without kinase, and
the data were expressed as a percentage of the control sample containing the
solvent.
For the ATP kinetics, the same methodology was applied as above, except that the
ATP concentration ranged from 1.25 to 40mM. The amount of incorporated 32P was
calculated from the standard line. The Km, Ki and Vmax values were calculated with
Prism5 software (GraphPad Software) using the competitive inhibition model.
Inhibitory proﬁling against 275 recombinant kinases. The effects of FINDY
against 275 kinases, listed in Supplementary Table 1, at an inhibitor concentration
of 10mM, were tested using the QuickScout Screening Assist Mobility Shift Assay
or an immobilized metal ion afﬁnity-based ﬂuorescence polarization screening
express kit with ATP concentration at Km or 1mM (Carna Biosciences). Detailed
information on the assay conditions is available on the website of Carna Bios-
ciences (http://www.carnabio.com).
Docking simulation. We selected the crystal structure of the human DYRK1A/
INDY complex (RCSB Protein Data Bank accession code 3ANQ)16 as the starting
model for the simulation. Docking simulations of RD0392 to DYRK1A were
performed with CDOCKER and related modules in Discovery Studio 3.0
(Accelrys). As the same procedure failed to produce any reasonable binding model
for FINDY, its complex with DYRK1A was built by manually modifying that for
DYRK1A/RD0392 obtained above, maintaining the common moiety of the two
compounds. The energy of the hypothetical DYRK1A/FINDY complex was then
minimized with the same program suite.
Statistical analysis. Statistical analysis of the experimental data (Figs 6b and 7
and Supplementary Figs 7e, 9e and 10) was performed with the Mann–Whitney U-
test. The data in Fig. 6d were analysed with the paired t-test. The results are shown
as means±s.d. with P values (*Po0.05, **Po0.01, ***Po0.001). The data were
ﬁtted to a four-parameter logistic curve (variable slope) for Hill slope determina-
tion, from which the IC50 and EC50 values were calculated using Prism 6.0
(GraphPad Software).
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